Allspring Global Investments Holdings LLC Purchases 2,169 Shares of AbbVie Inc. $ABBV

Allspring Global Investments Holdings LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 0.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 441,647 shares of the company’s stock after purchasing an additional 2,169 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in AbbVie were worth $94,945,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ABBV. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the 4th quarter worth about $28,000. Westend Capital Management LLC acquired a new stake in shares of AbbVie during the 4th quarter valued at about $29,000. Imprint Wealth LLC increased its stake in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Legacy Wealth Managment LLC ID raised its position in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in AbbVie in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Trading Up 0.1%

AbbVie stock opened at $254.53 on Friday. The company has a market cap of $449.70 billion, a PE ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 1 year low of $184.63 and a 1 year high of $261.64. The company’s 50-day moving average is $229.80 and its two-hundred day moving average is $221.94.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 EPS. Research analysts forecast that AbbVie Inc. will post 14.16 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

Analyst Ratings Changes

A number of research firms have weighed in on ABBV. Bank of America lifted their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a report on Friday, July 10th. Royal Bank Of Canada boosted their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Canaccord Genuity Group increased their price objective on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Citigroup increased their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $267.67.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.